Where is the most reliable place to buy amivantamab?

Introduction: Amivantamab, sold under the trade name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific Epidermal growth factor (EGF) receptor-directed and mesenchymal-epithelial transition (MET) receptor-directed antibodies, the first to treat adult patients with non-small cell lung cancer whose tumors harbor a specific type of genetic mutation called the epidermal growth factor receptor (EGFR) Exon 20 insertion mutation.

Where to buy amivantamab more reliably

1. Hospital: has not yet been officially launched in mainland China. Patients can go to hospitals in countries and regions where amivantamab is already on the market. After the doctor issues a medical prescription, they can purchase amivantamab directly in the hospital pharmacy.

2. Pharmacies: Patients can go to pharmacies in countries and regions where evantuzumab is already on the market to inquire whether they can buy evantuzumab.

3. Participate in clinical trials: Patients can consult their doctors or relevant medical institutions to find out whether there are ongoing clinical trials of evantumumab. If they meet the enrollment conditions, participating in the clinical trial may have the opportunity to obtain evantumumab for free.

4. Medical service institutions: Some domestic medical service institutions cooperate with pharmaceutical companies and may provide purchase channels for evantumumab. You can consult customer service personnel to find out whether evantumumab can be purchased, as well as specific price and other information.

Usage and dosage of evantuzumab

Premedication should be given before each infusion of evantuzumab, that is, diphenhydramine, acetaminophen, dexamethasone, or methylprednisolone. For patients weighing <80 kg, the dose on Week 1, Day 1 is 350 mg IV x 1 dose, and on Week 1, Day 2, the dose is 700 mg IV x 1 dose. 1050 mg intravenously every week during weeks 2-4, and 1050 mg intravenously every 2 weeks during weeks 5 and thereafter until disease progression or unacceptable toxicity.

For patients weighing ≥80 kg, the dose on day 1 of week 1 is 350 mg intravenously x 1 dose, and the dose on day 2 of week 1 is 1050 mg intravenous x 1 dose. 1,400 mg intravenously every week during weeks 2-4, and 1,400 mg intravenously every 2 weeks during weeks 5 and thereafter until disease progression or unacceptable toxicity.